Vi-Jon Talc Mesothelioma Case Settles in California
A California talc mesothelioma trial captioned Maricich Jr. et al. v. Chattem, Inc. settled January 21, 2026 after weeks of testimony.
A California talcum powder mesothelioma case captioned Maricich Jr. et al. v. Chattem, Inc. settled on January 21, 2026, after weeks of testimony in Alameda County Superior Court. The settlement came roughly two weeks into trial, with terms that remain undisclosed.
The Case
John E. Maricich, Jr. and his spouse Kym Maricich Benedict filed the lawsuit in 2025 in Alameda County Superior Court under docket number 25CV116787. The complaint alleged that Maricich developed sarcomatoid malignant mesothelioma after long-term use of talcum powder products.
According to the docket, the original complaint named 17 defendants across the manufacturing, supply, and retail chain, including Chattem, Inc. as the lead caption defendant, along with Vi-Jon, Inc., CVS Pharmacy Inc., and Walmart Inc. The case proceeded through weeks of testimony in early January 2026 before reaching a settlement on January 21, 2026. The terms of the agreement were not disclosed.
What the Complaint Alleged
The lawsuit alleged that talcum powder products used by Maricich contained asbestos or asbestiform fibers that caused his mesothelioma. Court filings identify Vi-Jon-supplied private-label powders, including CVS-brand talcum powder, among the products at issue.
Vi-Jon, Inc. is a St. Louis-based manufacturer and supplier of private-label personal care products for major retailers. The company’s current consumer powder products are marketed as talc-free, so the claims in this case center on historical product formulations rather than current retail offerings.
Sarcomatoid mesothelioma is one of three main cell types of the disease, alongside epithelioid and biphasic. It tends to grow more aggressively and is generally more resistant to standard treatments than the epithelioid subtype. Cell type is confirmed through biopsy and pathology review.
Broader Talc Litigation Context
This case is part of the larger wave of talcum powder litigation that has produced significant verdicts against product manufacturers and suppliers:
| Recent Verdict | Amount | Product |
|---|---|---|
| Craft v. Johnson and Johnson (Dec 2025) | $1.56 billion | Johnson’s Baby Powder |
While Johnson and Johnson has faced the largest number of talc lawsuits, suppliers of private-label and retail-brand talcum powder products have also been named in mesothelioma and ovarian cancer litigation across multiple states.
Why This Case Matters
The Maricich settlement is notable for several reasons.
The case focused on private-label talcum powder products rather than a nationally branded J&J product. Most high-profile talc trials have involved Johnson and Johnson, so resolutions involving other companies in the talc supply chain offer a separate data point for the wider docket.
Unlike many talc cases that involve ovarian cancer claims, Maricich alleged mesothelioma, a cancer linked to asbestos exposure. Mesothelioma claims in talc litigation carry particular significance because they connect consumer products to a known carcinogen.
The case also resolved while the federal talc multidistrict litigation in New Jersey prepares for further bellwether proceedings, adding another settlement to the public record for attorneys evaluating non-J&J talc claims.
Federal Talc Trials Ahead
A separate federal bellwether trial involving talcum powder claims is expected in the New Jersey multidistrict litigation, which consolidates tens of thousands of cases. A ruling allowing expert testimony in those cases removed a major hurdle to federal trials proceeding.
The Maricich settlement, while involving different products and defendants than the J&J litigation, reflects a broader pattern of talc cases resolving through confidential agreements rather than jury verdicts.
Related Reading
- Federal Judge Allows Expert Testimony in J&J Talc Lawsuits
- J&J Talc Verdicts in 2025
- Talcum Powder Lawsuits Guide
- Craft v. Johnson and Johnson $1.56 Billion Baltimore Verdict
References
Superior Court of California, County of Alameda (via PlainSite). (2025). Maricich Jr. et al. v. Chattem, Inc., Individually et al. (docket 25CV116787).
https://www.plainsite.law/dockets/5nfmesigv/superior-court-of-california-county-of-alameda/maricich-jr-et-al-v-chattem-inc-individually-et-al/
Superior Court of California, County of Alameda. (2025). Asbestos Litigation Information.
https://www.alameda.courts.ca.gov/general-information/asbestos-litigation
Reader Q&A
Frequently Asked Questions
What happened in the Maricich talc case?
John E. Maricich, Jr. and his spouse Kym Maricich Benedict filed suit in 2025 in Alameda County Superior Court (docket 25CV116787), captioned Maricich Jr. et al. v. Chattem, Inc. The complaint alleged that talcum powder products contained asbestos and caused Maricich’s sarcomatoid mesothelioma. Trial began in early January 2026 and the case settled on January 21, 2026. The settlement terms were not disclosed.
Who were the defendants?
The original complaint named 17 defendants across the manufacturing, supply, and retail chain, including Chattem, Inc. as the lead caption defendant, Vi-Jon, Inc., CVS Pharmacy Inc., and Walmart Inc.
How does this case relate to broader talc litigation?
Most talc lawsuits involve Johnson and Johnson’s Baby Powder, which has faced billions in verdicts. The Maricich case is notable because it focused on private-label talcum powder products rather than a nationally branded J&J product, and it resolved by confidential settlement rather than a jury verdict.
What is the connection between talcum powder and mesothelioma?
Some talcum powder products have been found to contain asbestos, a known carcinogen. Asbestos exposure is the primary cause of mesothelioma, a cancer of the lining of the lungs and abdomen. Talc and asbestos are minerals that can form in close proximity underground, and cross-contamination in historical talc mining has been documented in multiple studies.
How close are we to a cure for mesothelioma?
No cure exists for mesothelioma as of 2026. Approved first-line treatments include nivolumab plus ipilimumab immunotherapy (FDA-approved, with 3-year PFS of 14% vs. 1% for chemotherapy) and pembrolizumab plus chemotherapy (ORR 22% vs. 6%). Over 80 active clinical trials test emerging therapies like enzyme therapy (ADI-PEG20 extended survival 4-fold at 3 years), cancer vaccines (UV1 doubled response rates), and targeted therapies, with median survival reaching 18+ months in some multimodal approaches. Research shows improved outcomes but no evidence of curative potential yet.
Who is the longest survivor of pleural mesothelioma?
Sissy Hoffman is reported as the longest survivor of pleural mesothelioma, diagnosed in 1996 and living 29 years until her death in January 2025 at age 73. She underwent extrapleural pneumonectomy surgery and returned to teaching afterward. Other long-term pleural survivors include Heather von St. James (20 years as of 2025) and Tim Crisler (20 years). Median survival for pleural mesothelioma remains 14-21 months.
What is the new drug trial for mesothelioma?
The HIT-MESO trial, launched in March 2026, is the first randomized UK clinical trial testing proton beam therapy (PBT) for people with mesothelioma to potentially raise two-year survival from 30% to 50%. The ATOMIC-Meso trial showed pegargiminase (ADI-PEG20) combined with chemotherapy extended three-year survival four times longer than chemotherapy alone in 2024 results. Other active trials include a National Cancer Institute study of mesothelin-targeted TNhYP218 CAR T-cell therapy and phase III testing of volrustomig (MEDI5752) with carboplatin plus pemetrexed. Over 80 trials are recruiting for emerging therapies like enzyme inhibitors and targeted drugs. Details on eligibility and locations appear on ClinicalTrials.gov.
What new cancer drug has a 100% success rate?
Dostarlimab (Jemperli), a PD-1 inhibitor immunotherapy, achieved 100% clinical complete remission in all 42 people with mismatch repair-deficient (dMMR) locally advanced rectal cancer who completed treatment in a phase 2 trial at Memorial Sloan Kettering Cancer Center. No evidence of disease was detected via imaging, endoscopy, and biopsy after six months of treatment, with sustained responses up to four years and minimal side effects; none required chemotherapy, radiation, or surgery. These results were updated in June 2024 at ASCO, but dostarlimab applies only to this rare dMMR rectal cancer subset (5-10% of cases), not other cancers or tumor types ,. Larger trials are ongoing to confirm durability and broader applicability (NCT02997228 on ClinicalTrials.gov).